Almotriptan Pregnancy and Breastfeeding Warnings
Brand names: Axert
Medically reviewed by Drugs.com. Last updated on Aug 14, 2023.
Almotriptan Pregnancy Warnings
This drug should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
US FDA pregnancy category: C
When this drug was given to animals in doses 80 to nearly 1000 times the recommended daily dose for humans, it caused developmental toxicity. The incidence of embryolethality increased at the highest dose. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Almotriptan Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Yes
Comments: Infant exposure may be minimized by avoiding breastfeeding for 24 hours.
There are no published experiences with use during breastfeeding. If this drug is used by the mother, it is not considered necessary to discontinue breastfeeding, however alternate drugs may be preferred, especially while nursing a newborn or preterm infant. Levels of this drug in rat milk were up to 7 times higher than in rat plasma.
See also
References for pregnancy information
- (2001) "Product Information. Axert (almotriptan)." Pharmacia and Upjohn
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
References for breastfeeding information
- (2001) "Product Information. Axert (almotriptan)." Pharmacia and Upjohn
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
